So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

RBC Capital confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145 refers to a BTK degrader that is ...

ORLANDO -- Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Dennis Rader, the BTK serial killer whose self-given nickname stands for “Bind, Torture, Kill,” played a cat and mouse game with investigators and reporters for decades before he was caught. But Rader ...

Police said Saturday they have arrested a man they believe is the notorious BTK serial killer who terrorized Wichita throughout the 1970s and then resurfaced about a year ago after 25 years of silence ...

Dec. 2, 2004 — -- Some believe Wichita's mysterious "BTK" serial killer has taunted investigators since he resurfaced almost nine months ago after a 25-year absence. But will his taunts lead to ...

Dennis Rader, the BTK serial killer whose self-given nickname stands for “Bind, Torture, Kill,” played a cat and mouse game with investigators and reporters for decades before he was caught. But Rader ...